CapsoVision, Inc. filed its quarterly report on Form 10-Q with the SEC on August 13, 2026, covering the period ended June 30, 2026, disclosing condensed financial statements and related disclosures for the three and six months ended on that date.

Key Highlights

  • Shares outstanding: As of August 12, 2026, the company had 50,046,913 shares of common stock, $0.001 par value per share, outstanding.
  • Total assets: Total assets were $18,569 thousand as of June 30, 2026, compared to $18,164 thousand as of December 31, 2025.
  • Cash position: Cash and cash equivalents stood at $9,077 thousand as of June 30, 2026, down from $10,112 thousand at December 31, 2025.
  • Inventory: Inventory increased to $4,704 thousand as of June 30, 2026, from $2,987 thousand at December 31, 2025.
  • Accounts receivable: Accounts receivable, net, were $2,265 thousand as of June 30, 2026, compared to $2,498 thousand at December 31, 2025.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

CapsoVision Reports Balance Sheet Shift as Inventory Rises in First Half of 2026

According to the filing, CapsoVision, Inc. (NASDAQ:CV), a Delaware-incorporated medical device company headquartered at 18805 Cox Avenue, Suite 250, Saratoga, CA, reported total current assets of $17,280 thousand as of June 30, 2026, up from $16,669 thousand at December 31, 2025. The increase was driven primarily by a rise in inventory, which grew to $4,704 thousand from $2,987 thousand over the same period. Cash and cash equivalents declined to $9,077 thousand from $10,112 thousand, and accounts receivable, net, fell to $2,265 thousand from $2,498 thousand.

The filing also reported non-current assets including property and equipment, net, of $562 thousand (down from $611 thousand at year-end 2025), operating lease right-of-use assets of $651 thousand (down from $843 thousand), and other long-term assets of $76 thousand (up from $41 thousand). Total assets as of June 30, 2026, were $18,569 thousand versus $18,164 thousand at December 31, 2025, according to the condensed balance sheet.

The company disclosed that it is not a shell company and confirmed filing compliance for the preceding 12 months. The filing noted, among the company's forward-looking statements, topics including its ability to continue as a going concern, future capital requirements, and expected timing for FDA 510(k) clearance activities. The company cautioned that those statements are subject to risks and uncertainties as described in its Risk Factors section, and it noted it is "not obligated to publicly update or revise any forward-looking statement."

What Was Disclosed

CapsoVision filed its Form 10-Q for the quarter ended June 30, 2026, disclosing unaudited condensed balance sheet data showing total assets of $18,569 thousand, a cash balance of $9,077 thousand, and 50,046,913 shares of common stock outstanding as of August 12, 2026.